Oil prices slipped early Monday as signs of a pause in the U.S.-Iran conflict eased concerns regarding further supply disruptions in the Middle East. President Trump has put off a major escalation of ...

Dear Quentin, I am a 63-year-old semiretired physician. Years ago I said that I would gladly opt out of Social Security if, in exchange, the government removed the contribution li ...

The busiest week of corporate earnings is coming up, with 177 S&P 500 companies set to report in the days ahead.

On June 30, I sold all of my Vanguard Short-Term Corporate Bond Index Fund Admiral Shares, which were valued at $80,000. I ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern ...

U.S. 3 Year Treasury Note 0.0000 4.3750% U.S. 5 Year Treasury Note 0.0000 4.4390% U.S. 7 Year Treasury Note 0.0000 4.5540% ...

The “Mag Seven” stocks have become the “Bag Seven” — or worse. That was fun while it lasted.

Five days before the Federal Reserve’s interest-rate committee meets, there is a lot of uncertainty about what the central bank will do. Markets see a one-in-three chance of a rate hike in July, with ...

NextEra Energy recorded a big jump in profit for the second quarter from climbing revenue and a decline in costs. The clean-energy company posted a profit of $3.14 billion, or $1.50 a share, up from ...

Bluerock Acquisition Corp. II has filed for an initial public offering. The special-purpose acquisition company said it will sell 15 million units at $10 apiece, according to a filing with the ...

Shares of Outlook Therapeutics posted wide swings as the Food and Drug Administration approved the company's Lytenava for treatment of neovascular age-related macular degeneration.

The stock's fall snapped a five-day winning streak.